25-085-NCP: SIGNAL-ER 101: Signatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

Title
SIGNAL-ER 101: Signatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer
Principal Investigator
Jiang, Bei
Phase
II
Age Group
Adult
Applicable Disease Sites
Breast Cancer
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Kaitlyn Hager
Research Nurse
Email:

View on ClinicalTrials.gov